Overview

Bevacizumab for the Treatment of Corneal Neovascularization

Status:
Unknown status
Trial end date:
2012-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the current study is to assess the efficacy and safety of the inhibitory effect of bevacizumab (Avastin) with different routes including topical and subconjunctival application on corneal neovascularization in the human eyes.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Chang Gung Memorial Hospital
Treatments:
Bevacizumab
Criteria
Inclusion Criteria:

- Significant unilateral or bilateral corneal neovascularization that extending over the
limbus at least 2mm.

- The underlying etiologies that caused corneal neovascularization included post
penetrating keratoplasty (PKP), ocular surface reconstruction , trauma, infectious or
non-infectious corneal ulcer.

- Corneal neovascularization induced lipid keratopathy, corneal edema, or irregular
corneal surface. The best-corrected visual acuity was less than 20/25.

- Post-PSP or ocular surface reconstruction corneal neovascularization that had no
associated lipid keratopathy, no corneal edema, or corneal irregularity. But the
neovascularization was highly possible to cause graft rejection.

- The corneal neovascularization was refractory to other medical treatment.

- The patient had received PKP or other corneal surgeries mort than half a year ago and
was not in the acute post-operation phase.

- The patient had no active endophthalmitis, glaucoma with uncontrolled intraocular
pressure, or vitreoretinal diseases.

- The patient signed inform consent to have regular follow up and treatment.

Exclusion Criteria:

- The neovascularization had clinical improvement three months before the first
injection.

- The lipid keratopathy had clinical improvement three months before the first
injection.

- The patient that suspected to have poor visual outcome or had already been light sense
negative Glaucoma patient that had uncontrolled intraocular pressure.

- Poor corneal epithelialization.

- Patient that had systemic disease which was not suitable for bevacizumab use.

- Pregnant patient.